Lund, Sweden, 27 August. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at Pareto Securities’ 17th Annual Healthcare Conference 2026 in Stockholm, at 12:45-13:05 CEST, on Wednesday 2 September, as well as participating in a panel discussion later that day at 14:50-15:10 CEST. Read more…
Lund, Sweden, August 21, 2026. Hansa Biopharma AB (publ) (“Hansa” or the “Company”) today announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to a potential initial public offering of American Depositary Shares (“ADSs”), representing the Company’s ordinary shares, in the United […]
ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration Based on PK data the therapeutic dose is expected to be ≤10mg once daily To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), […]
Lund, Sweden, August 18, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). “This first commercial living donor transplant patient in Australia represents an important milestone […]
Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance Recent positive interim results showed safety and immunogenicity with early signals of activity Full week-100 results from Part 1 of VacSYn trial expected in H2 2026 Lausanne, Switzerland, August 11, 2026 – AC Immune SA (NASDAQ: ACIU), […]
